What question did this study set out to answer?

To evaluate the current management strategies and outcomes for pulmonary hypertension in pregnancy.

March 27, 2026Santosh University Journal of Health SciencesOpen Access

Pulmonary hypertension in pregnancy in the modern therapy era: A systematic review of translational management framework

View Full Paper

Ask AI

Bookmark

Key result

Prostacyclin and PDE-5 inhibitors improve survival in pregnant women with PH at specialized centers.

Why the study?

Pulmonary hypertension in pregnancy continues to carry a high risk of maternal and neonatal morbidity and mortality despite modern therapeutic progress.

Does targeted pulmonary vasodilator therapy improve maternal and fetal outcomes in pregnant women with pulmonary hypertension?

Population

More than 2500 pregnancies across 33 studies

Comparison

Targeted pulmonary vasodilator therapy management

Design

Systematic review

Authors

WAWiku AndonotopoTexas Tech University ELEfendi LukasHasanuddin University MPMochammad Besari Adi PramonoDr. Kariadi Hospital

Discussion

Member takes

Implication

Supports specialized center care with prostacyclin and PDE-5 inhibitors in pregnant PH; extends low-certainty evidence but leaves high neonatal morbidity unaddressed.

Key Points

To evaluate the current management strategies and outcomes for pulmonary hypertension in pregnancy.
Conducted a systematic review according to PRISMA guidelines.
Performed comprehensive searches on PubMed, Scopus, and Embase from 2005 to May 2025.
Included observational cohorts, registries, and reviews focusing on maternal or fetal outcomes under treatment.
Identified 33 eligible studies involving over 2500 pregnancies.
Improved survival noted with specialized management using prostacyclin and phosphodiesterase-5 inhibitors.
High rates of preterm delivery and NICU admissions persisted despite improved neonatal outcomes.

Structured PICO

Does targeted pulmonary vasodilator therapy improve maternal and fetal outcomes in pregnant women with pulmonary hypertension?

Population

Pregnant women with pulmonary hypertension (33 studies encompassing more than 2500 pregnancies)

Intervention

Targeted pulmonary vasodilator therapy (prostacyclin-based regimens and phosphodiesterase-5 inhibitors) managed in specialized centers

Outcome

Maternal or fetal outcomes (morbidity and mortality)hard clinical

Contemporary management of pulmonary hypertension in pregnancy using a multidisciplinary, prostacyclin-anchored approach in specialized centers improves maternal survival, though neonatal morbidity remains high.

Cite This Study

Andonotopo et al. (2025) studied this question. Prostacyclin-based regimens and phosphodiesterase-5 inhibitors improve survival in pregnant women with pulmonary hypertension when managed in specialized centers.

synapsesocial.com/papers/69c620be15a0a509bde195bb https://doi.org/10.4103/sujhs.sujhs_80_25

View Full Paper

Ask AI

Bookmark

Implication

Supports specialized center care with prostacyclin and PDE-5 inhibitors in pregnant PH; extends low-certainty evidence but leaves high neonatal morbidity unaddressed.

Pulmonary hypertension in pregnancy in the modern therapy era: A systematic review of translational management framework

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Pulmonary hypertension in pregnancy in the modern therapy era: A systematic review of translational management framework

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider